{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:30:51Z","timestamp":1790220651179,"version":"4.1.0"},"reference-count":149,"publisher":"Georg Thieme Verlag KG","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lipoprotein(a) [Lp(a)] is a circulating plasma lipoprotein with structural similarities to low-density lipoprotein (LDL), distinguished by the addition of apolipoprotein(a) to the LDL structure. Lp(a) levels are approximately 80% genetically determined, and distinct components of this complex particle are thought to confer atherogenic, inflammatory, and antifibrinolytic properties contributing to cardiovascular risk. A growing body of evidence has shown a causal association between elevated Lp(a) levels and both atherosclerotic cardiovascular disease (ASCVD) and valvular aortic stenosis. However, the link with venous thromboembolism (VTE) (encompassing deep vein thrombosis [DVT] and pulmonary embolism [PE]) has been less clear. Although in vitro studies suggest antifibrinolytic and prothrombotic properties for Lp(a), clinical and genetic studies have yielded inconsistent results related to thrombogenicity, with some studies suggesting an association with VTE only with very high Lp(a) levels. The effect of Lp(a) levels on outcomes in patients with incident VTE has not been comprehensively investigated. Although there are currently no approved therapies specifically targeting Lp(a) reduction, at least five agents are in development, with preliminary data demonstrating reductions in Lp(a) levels of up to 98%. The impact of these therapies on VTE events remains unknown. In turn, other lipid-modifying agents, which have no effect on reducing Lp(a), such as statins, were shown to reduce incident VTE. This review summarizes the current evidence regarding the association between Lp(a) and VTE, focusing on its pathophysiology and critically analyzing the existing evidence from experimental, epidemiological, and genetic studies.<\/jats:p>","DOI":"10.1055\/a-2674-5114","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T22:51:48Z","timestamp":1755903108000},"page":"1069-1084","source":"Crossref","is-referenced-by-count":9,"title":["Lipoprotein(a) and Venous Thromboembolism: Association, Causality, and Medications"],"prefix":"10.1055","volume":"125","author":[{"given":"Mariana B.","family":"Pfeferman","sequence":"additional","affiliation":[{"name":"Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Rashedi","sequence":"additional","affiliation":[{"name":"Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science at the University of Liverpool, Liverpool John Moores University, and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom"},{"name":"Department of Clinical Medicine, Danish Center for Health Services Research, Aalborg University, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Weber","sequence":"additional","affiliation":[{"name":"Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universit\u00e4t (LMU), LMU University Hospital, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"O'Donoghue","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, TIMI Study Group, Brigham and Women's Hospital, Boston, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Nissen","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Victorian Heart Institute, Monash University, Clayton, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Natarajan","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Plutzky","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Libby","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Z.","family":"Goldhaber","sequence":"additional","affiliation":[{"name":"Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"},{"name":"Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Piazza","sequence":"additional","affiliation":[{"name":"Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"},{"name":"Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnood","family":"Bikdeli","sequence":"additional","affiliation":[{"name":"Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"},{"name":"Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"},{"name":"YNHH\/Yale Center for Outcomes Research and Evaluation (CORE), New Haven, Connecticut, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"G Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.atherosclerosis.2022.04.002","article-title":"Recent advances in demystifying the metabolism of lipoprotein(a)","volume":"349","author":"K Chemello","year":"2022","journal-title":"Atherosclerosis"},{"issue":"05","key":"ref3","doi-asserted-by":"crossref","first-page":"oeae064","DOI":"10.1093\/ehjopen\/oeae064","article-title":"Intra-individual variability in lipoprotein(a): the value of a repeat measure for reclassifying individuals at intermediate risk","volume":"4","author":"T Harb","year":"2024","journal-title":"Eur Heart J Open"},{"issue":"05","key":"ref4","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jacc.2024.10.081","article-title":"Intraindividual variability in serial lipoprotein(a) concentrations among placebo-treated patients in the OCEAN(a)-DOSE trial","volume":"85","author":"P Gaba","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"08","key":"ref5","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein (a)","volume":"57","author":"K Schmidt","year":"2016","journal-title":"J Lipid Res"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/clinchem\/hvaa247","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"67","author":"P R Kamstrup","year":"2021","journal-title":"Clin Chem"},{"key":"ref7","first-page":"3491764","article-title":"Lipoprotein(a) the insurgent: a new insight into the structure, function, metabolism, pathogenicity, and medications affecting lipoprotein(a) molecule","volume":"2020","author":"M M Jawi","year":"2020","journal-title":"J Lipids"},{"issue":"08","key":"ref8","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"F M van der Valk","year":"2016","journal-title":"Circulation"},{"issue":"10","key":"ref9","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1194\/jlr.M040733","article-title":"Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)","volume":"54","author":"G Leibundgut","year":"2013","journal-title":"J Lipid Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.atherosclerosis.2022.04.009","article-title":"Beyond fibrinolysis: the confounding role of Lp(a) in thrombosis","volume":"349","author":"M B Boffa","year":"2022","journal-title":"Atherosclerosis"},{"issue":"05","key":"ref11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41569-023-00947-2","article-title":"Lipoprotein(a), platelet function and cardiovascular disease","volume":"21","author":"H S Bhatia","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2015.08.002","article-title":"National lipid association annual summary of clinical lipidology 2016","volume":"10","author":"H E Bays","year":"2016","journal-title":"J Clin Lipidol"},{"issue":"11","key":"ref13","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"B G Nordestgaard","year":"2016","journal-title":"J Lipid Res"},{"issue":"20","key":"ref14","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/CIRCULATIONAHA.120.046524","article-title":"Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein(a) and modification by alirocumab: prespecified analysis of the odyssey outcomes randomized clinical trial","volume":"141","author":"G G Schwartz","year":"2020","journal-title":"Circulation"},{"issue":"24","key":"ref15","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"S M Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10557-015-6634-1","article-title":"Experimental animal models evaluating the causal role of lipoprotein(a) in atherosclerosis and aortic stenosis","volume":"30","author":"C Yeang","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"issue":"05","key":"ref17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.clinbiochem.2003.12.007","article-title":"Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models","volume":"37","author":"M B Boffa","year":"2004","journal-title":"Clin Biochem"},{"issue":"16","key":"ref18","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/eurheartj\/ehad055","article-title":"Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein","volume":"44","author":"P E Thomas","year":"2023","journal-title":"Eur Heart J"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank","volume":"41","author":"A P Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"16","key":"ref20","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.jacc.2024.02.031","article-title":"Lipoprotein(a) and long-term cardiovascular risk in a multi-ethnic pooled prospective cohort","volume":"83","author":"N D Wong","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"ref21","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1136\/heartjnl-2021-319044","article-title":"Lipoprotein(a) is robustly associated with aortic valve calcium","volume":"107","author":"Y Kaiser","year":"2021","journal-title":"Heart"},{"issue":"04","key":"ref22","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"S Erqou","year":"2009","journal-title":"JAMA"},{"issue":"09","key":"ref23","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1055\/a-1340-2109","article-title":"Lipoprotein(a) and cardiovascular outcomes in patients with previous myocardial infarction: a prospective cohort study","volume":"121","author":"Y X Cao","year":"2021","journal-title":"Thromb Haemost"},{"issue":"21","key":"ref24","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.jacc.2025.04.010","article-title":"Global variation in lipoprotein(a) levels among patients with coronary heart disease: insights from the INTERASPIRE study and implications for emerging Lp(a)-lowering therapies","volume":"85","author":"F Barkas","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"02","key":"ref25","doi-asserted-by":"crossref","first-page":"e002060","DOI":"10.1136\/openhrt-2022-002060","article-title":"Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease","volume":"9","author":"S E Nissen","year":"2022","journal-title":"Open Heart"},{"issue":"05","key":"ref26","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"P R Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"03","key":"ref27","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCGENETICS.113.000400","article-title":"Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort","volume":"7","author":"B J Arsenault","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"issue":"22","key":"ref28","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"P R Kamstrup","year":"2009","journal-title":"JAMA"},{"issue":"02","key":"ref29","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study","volume":"117","author":"P R Kamstrup","year":"2008","journal-title":"Circulation"},{"issue":"26","key":"ref30","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"R Clarke","year":"2009","journal-title":"N Engl J Med"},{"issue":"01","key":"ref31","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s40001-022-00825-6","article-title":"The relationship between lipoprotein(a) and risk of cardiovascular disease: a Mendelian randomization analysis","volume":"27","author":"S Wang","year":"2022","journal-title":"Eur J Med Res"},{"issue":"02","key":"ref32","doi-asserted-by":"crossref","first-page":"e0149427","DOI":"10.1371\/journal.pone.0149427","article-title":"Apolipoprotein(a) kringle-IV type 2 copy number variation is associated with venous thromboembolism","volume":"11","author":"E Sticchi","year":"2016","journal-title":"PLoS One"},{"issue":"33","key":"ref33","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","article-title":"High lipoprotein(a) and high risk of mortality","volume":"40","author":"A Langsted","year":"2019","journal-title":"Eur Heart J"},{"issue":"39","key":"ref34","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"F Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"issue":"03","key":"ref35","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1161\/ATVBAHA.111.242818","article-title":"Mechanistic view of risk factors for venous thromboembolism","volume":"32","author":"P H Reitsma","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"05","key":"ref36","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"M B Boffa","year":"2016","journal-title":"J Lipid Res"},{"issue":"08","key":"ref37","first-page":"529","article-title":"Lipoprotein (a) and vascular disease: thrombogenesis and atherogenesis","volume":"88","author":"G Y Lip","year":"1995","journal-title":"QJM"},{"issue":"22","key":"ref38","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1161\/CIRCULATIONAHA.120.045826","article-title":"Lipoprotein(a) in Alzheimer, atherosclerotic, cerebrovascular, thrombotic, and valvular disease: Mendelian randomization investigation","volume":"141","author":"S C Larsson","year":"2020","journal-title":"Circulation"},{"issue":"06","key":"ref39","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1055\/s-0036-1598002","article-title":"Lipoprotein(a) as a risk factor for venous thromboembolism: a systematic review and meta-analysis of the literature","volume":"43","author":"F Dentali","year":"2017","journal-title":"Semin Thromb Hemost"},{"issue":"01","key":"ref40","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jth.12056","article-title":"Lipoprotein(a), polymorphisms in the LPA gene, and incident venous thromboembolism among 21483 women","volume":"11","author":"J S Danik","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref41","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein (a) measurements for clinical application","volume":"57","author":"S M Marcovina","year":"2016","journal-title":"J Lipid Res"},{"issue":"20","key":"ref42","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/eurheartj\/ehx233","article-title":"Lipoprotein(a)","volume":"38","author":"A V Eckardstein","year":"2017","journal-title":"Eur Heart J"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.atherosclerosis.2022.04.001","article-title":"Oxidized phospholipid modification of lipoprotein(a): epidemiology, biochemistry and pathophysiology","volume":"349","author":"M L Koschinsky","year":"2022","journal-title":"Atherosclerosis"},{"issue":"05","key":"ref44","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/07853890.2020.1775287","article-title":"Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options","volume":"52","author":"A Rehberger Likozar","year":"2020","journal-title":"Ann Med"},{"issue":"20","key":"ref45","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/eurheartj\/ehx033","article-title":"Lipoprotein(a): the revenant","volume":"38","author":"B Gencer","year":"2017","journal-title":"Eur Heart J"},{"issue":"03","key":"ref46","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1055\/s-0037-1614490","article-title":"Comparison of the effects of Apo(a) kringle IV-10 and plasminogen kringles on the interactions of lipoprotein(a) with regulatory molecules","volume":"81","author":"S Xue","year":"1999","journal-title":"Thromb Haemost"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cca.2020.10.010","article-title":"Quantifying apolipoprotein(a) in the era of proteoforms and precision medicine","volume":"511","author":"L R Ruhaak","year":"2020","journal-title":"Clin Chim Acta"},{"issue":"02","key":"ref48","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00041433-200404000-00009","article-title":"Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity","volume":"15","author":"M L Koschinsky","year":"2004","journal-title":"Curr Opin Lipidol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2022.04.006","article-title":"Non-genetic influences on lipoprotein(a) concentrations","volume":"349","author":"B Enkhmaa","year":"2022","journal-title":"Atherosclerosis"},{"issue":"03","key":"ref50","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/MOL.0000000000000823","article-title":"Understanding the ins and outs of lipoprotein (a) metabolism","volume":"33","author":"M B Boffa","year":"2022","journal-title":"Curr Opin Lipidol"},{"issue":"09","key":"ref51","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1194\/jlr.R077693","article-title":"The metabolism of lipoprotein (a): an ever-evolving story","volume":"58","author":"G Reyes-Soffer","year":"2017","journal-title":"J Lipid Res"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"e50415","DOI":"10.2196\/50415","article-title":"Relationship between lipoprotein(a), renal function indicators, and chronic kidney disease: evidence from a large prospective cohort study","volume":"10","author":"Y Liu","year":"2024","journal-title":"JMIR Public Health Surveill"},{"issue":"24","key":"ref53","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"S Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2022.04.003","article-title":"Lipoprotein(a) beyond the kringle IV repeat polymorphism: the complexity of genetic variation in the LPA gene","volume":"349","author":"S Coassin","year":"2022","journal-title":"Atherosclerosis"},{"issue":"07","key":"ref55","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1194\/jlr.R051904","article-title":"Lipoprotein (a): impact by ethnicity and environmental and medical conditions","volume":"57","author":"B Enkhmaa","year":"2016","journal-title":"J Lipid Res"},{"issue":"12","key":"ref56","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","article-title":"Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups","volume":"139","author":"G Par\u00e9","year":"2019","journal-title":"Circulation"},{"issue":"09","key":"ref57","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jacc.2022.06.019","article-title":"Ancestry, lipoprotein(a), and cardiovascular risk thresholds: JACC review topic of the week","volume":"80","author":"S Tsimikas","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"09","key":"ref58","doi-asserted-by":"crossref","first-page":"e035353","DOI":"10.1161\/JAHA.124.035353","article-title":"Sex differences in the association between lipoprotein(a) and cardiovascular outcomes: the MGB Lp(a) registry","volume":"14","author":"G Kaur","year":"2025","journal-title":"J Am Heart Assoc"},{"issue":"09","key":"ref59","doi-asserted-by":"crossref","first-page":"100420","DOI":"10.1016\/j.jlr.2023.100420","article-title":"Reducing saturated fat intake lowers LDL-C but increases Lp(a) levels in African Americans: the GET-READI feeding trial","volume":"64","author":"H G Law","year":"2023","journal-title":"J Lipid Res"},{"issue":"06","key":"ref60","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S2213-8587(14)70006-3","article-title":"Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study","volume":"2","author":"B Sjouke","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"ref61","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1194\/jlr.M800174-JLR200","article-title":"A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma","volume":"49","author":"C Bergmark","year":"2008","journal-title":"J Lipid Res"},{"issue":"03","key":"ref62","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jacc.2023.10.039","article-title":"Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-based genetic analysis","volume":"83","author":"E Bj\u00f6rnson","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"05","key":"ref63","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41569-018-0153-2","article-title":"Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease","volume":"16","author":"M B Boffa","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"ref64","doi-asserted-by":"crossref","first-page":"e033654","DOI":"10.1161\/JAHA.123.033654","article-title":"Genetics and pathophysiological mechanisms of lipoprotein(a)-associated cardiovascular risk","volume":"13","author":"A S Volgman","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"01","key":"ref65","first-page":"386","article-title":"Plasma lipoproteins, hemostasis and thrombosis","volume":"86","author":"J H Griffin","year":"2001","journal-title":"Thromb Haemost"},{"issue":"26","key":"ref66","doi-asserted-by":"crossref","first-page":"23260","DOI":"10.1074\/jbc.M302780200","article-title":"Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces","volume":"278","author":"M A Hancock","year":"2003","journal-title":"J Biol Chem"},{"issue":"12","key":"ref67","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1111\/j.1538-7836.2008.03183.x","article-title":"Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation","volume":"6","author":"N T Feric","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref68","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1538-7836.2006.01903.x","article-title":"Lipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis","volume":"4","author":"A Undas","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref69","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1016\/S0021-9258(18)52266-3","article-title":"Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis","volume":"266","author":"O R Etingin","year":"1991","journal-title":"J Biol Chem"},{"issue":"03","key":"ref70","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1161\/ATVBAHA.123.318286","article-title":"Clot or not? Reviewing the reciprocal regulation between lipids and blood clotting","volume":"44","author":"Z Zhang","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"03","key":"ref71","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1096\/fj.05-4857fje","article-title":"Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin","volume":"20","author":"S N Sotiriou","year":"2006","journal-title":"FASEB J"},{"issue":"10","key":"ref72","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood.V98.10.2980","article-title":"Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis","volume":"98","author":"N M Caplice","year":"2001","journal-title":"Blood"},{"issue":"03","key":"ref73","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/jth.13925","article-title":"Oxidized low-density lipoprotein in inflammation-driven thrombosis","volume":"16","author":"G Obermayer","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref74","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1055\/s-0037-1615654","article-title":"Binding of recombinant apolipoprotein(a) to human platelets and effect on platelet aggregation","volume":"85","author":"C Mart\u00ednez","year":"2001","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref75","doi-asserted-by":"crossref","first-page":"16609","DOI":"10.1038\/s41598-022-21121-7","article-title":"Independent association of Lp(a) with platelet reactivity in subjects without statins or antiplatelet agents","volume":"12","author":"H Liu","year":"2022","journal-title":"Sci Rep"},{"issue":"04","key":"ref76","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/mps3040067","article-title":"Fibrin clot formation and lysis in plasma","volume":"3","author":"J B Larsen","year":"2020","journal-title":"Methods Protoc"},{"issue":"6222","key":"ref77","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/339303a0","article-title":"Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis","volume":"339","author":"K A Hajjar","year":"1989","journal-title":"Nature"},{"issue":"6222","key":"ref78","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/339301a0","article-title":"A potential basis for the thrombotic risks associated with lipoprotein(a)","volume":"339","author":"L A Miles","year":"1989","journal-title":"Nature"},{"issue":"02","key":"ref79","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/01.ATV.10.2.240","article-title":"Lipoprotein(a), fibrin binding, and plasminogen activation","volume":"10","author":"J Loscalzo","year":"1990","journal-title":"Arteriosclerosis"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2018.07.002","article-title":"Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen on the surface of vascular endothelial and smooth muscle cells","volume":"169","author":"R Romagnuolo","year":"2018","journal-title":"Thromb Res"},{"issue":"05","key":"ref81","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1161\/01.CIR.96.5.1612","article-title":"Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo","volume":"96","author":"B J Biemond","year":"1997","journal-title":"Circulation"},{"issue":"03","key":"ref82","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nm0395-256","article-title":"Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis","volume":"1","author":"T M Palabrica","year":"1995","journal-title":"Nat Med"},{"issue":"8013","key":"ref83","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s41586-024-07387-z","article-title":"Discovery of potent small-molecule inhibitors of lipoprotein(a) formation","volume":"629","author":"N Diaz","year":"2024","journal-title":"Nature"},{"issue":"09","key":"ref84","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1161\/01.ATV.18.9.1393","article-title":"Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN","volume":"18","author":"M L Rand","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"09","key":"ref85","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/nm1626","article-title":"Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype","volume":"13","author":"E A Podrez","year":"2007","journal-title":"Nat Med"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2741\/1194","article-title":"Apoprotein (A) antagonises THE GPIIB\/IIIA receptor on collagen and adp-stimulated human platelets","volume":"9","author":"D E Barre","year":"2004","journal-title":"Front Biosci"},{"issue":"05","key":"ref87","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1161\/01.ATV.16.5.648","article-title":"Lipoprotein(a) inhibits collagen-induced aggregation of thrombocytes","volume":"16","author":"A Gries","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"08","key":"ref88","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.amjmed.2003.06.005","article-title":"Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism","volume":"115","author":"R Marcucci","year":"2003","journal-title":"Am J Med"},{"issue":"10","key":"ref89","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1182\/blood.V96.10.3364","article-title":"Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism","volume":"96","author":"M von Depka","year":"2000","journal-title":"Blood"},{"issue":"02","key":"ref90","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1055\/s-0032-1301420","article-title":"The thrombophilic pattern of different clinical manifestations of venous thromboembolism: a survey of 443 cases of venous thromboembolism","volume":"38","author":"E Grifoni","year":"2012","journal-title":"Semin Thromb Hemost"},{"issue":"03","key":"ref91","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/14017431.2019.1612087","article-title":"Lipoprotein(a) is not associated with venous thromboembolism risk","volume":"53","author":"S K Kunutsor","year":"2019","journal-title":"Scand Cardiovasc J"},{"issue":"05","key":"ref92","first-page":"923","article-title":"Lipid levels do not influence the risk of venous thromboembolism. Results of a population-based cohort study","volume":"108","author":"I M van Schouwenburg","year":"2012","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref93","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1055\/s-0041-1732803","article-title":"Role of increased lipoprotein (a) in retinal vein occlusion: a systematic review and meta-analysis","volume":"5","author":"F Paciullo","year":"2021","journal-title":"TH Open"},{"issue":"01","key":"ref94","doi-asserted-by":"crossref","first-page":"e005623","DOI":"10.1161\/CIRCOUTCOMES.119.005623","article-title":"Mendelian randomization in cardiovascular research: establishing causality when there are unmeasured confounders","volume":"14","author":"K JL Bell","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2022.04.013","article-title":"Mendelian randomization: principles and its usage in Lp(a) research","volume":"349","author":"C Lamina","year":"2022","journal-title":"Atherosclerosis"},{"issue":"11","key":"ref96","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/s41588-019-0519-3","article-title":"Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease","volume":"51","author":"D Klarin","year":"2019","journal-title":"Nat Genet"},{"issue":"16","key":"ref97","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1161\/CIRCULATIONAHA.122.059675","article-title":"Cross-ancestry investigation of venous thromboembolism genomic predictors","volume":"146","author":"F Thibord","year":"2022","journal-title":"Circulation"},{"issue":"24","key":"ref98","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2019.10.019","article-title":"Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes","volume":"74","author":"D F Gudbjartsson","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"03","key":"ref99","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.thromres.2010.06.007","article-title":"Serum lipoprotein (a) levels in patients with first unprovoked venous thromboembolism is not associated with subsequent risk of recurrent VTE","volume":"126","author":"M A Rodger","year":"2010","journal-title":"Thromb Res"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"808605","DOI":"10.3389\/fcvm.2022.808605","article-title":"Lipoprotein(a) and pulmonary embolism severity\u2014a retrospective data analysis","volume":"9","author":"P Gressenberger","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"01","key":"ref101","doi-asserted-by":"crossref","first-page":"25962","DOI":"10.1038\/s41598-024-77669-z","article-title":"Lipoprotein (a) is not associated with thrombus burden derived from CT pulmonary angiography in patients with acute pulmonary embolism","volume":"14","author":"P Gressenberger","year":"2024","journal-title":"Sci Rep"},{"issue":"01","key":"ref102","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11239-018-1769-0","article-title":"Elevated lipoprotein(a) as a new risk factor of cerebral venous sinus thrombosis: association with fibrin clot properties","volume":"47","author":"A A Skuza","year":"2019","journal-title":"J Thromb Thrombolysis"},{"issue":"06","key":"ref103","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jacbts.2016.08.007","article-title":"Lipoprotein (a): a frustrating final frontier in lipid management?","volume":"1","author":"P Libby","year":"2016","journal-title":"JACC Basic Transl Sci"},{"issue":"6405","key":"ref104","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/360670a0","article-title":"Atherogenesis in transgenic mice expressing human apolipoprotein(a)","volume":"360","author":"R M Lawn","year":"1992","journal-title":"Nature"},{"issue":"07","key":"ref105","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.108.786822","article-title":"Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice","volume":"118","author":"E Merki","year":"2008","journal-title":"Circulation"},{"issue":"01","key":"ref106","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): resurrected by genetics","volume":"273","author":"F Kronenberg","year":"2013","journal-title":"J Intern Med"},{"issue":"01","key":"ref107","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-0037-1614640","article-title":"Evidence that modifications of Lp(a) in vivo inhibit plasmin formation on fibrin\u2014a study with individual plasmas presenting natural variations of Lp(a)","volume":"82","author":"T Soulat","year":"1999","journal-title":"Thromb Haemost"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.atherosclerosis.2022.06.1020","article-title":"Oxidized phospholipids on apolipoprotein B-100 versus plasminogen and risk of coronary heart disease in the PROCARDIS study","volume":"354","author":"R Clarke","year":"2022","journal-title":"Atherosclerosis"},{"issue":"12","key":"ref109","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1194\/jlr.P094763","article-title":"Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis","volume":"60","author":"M B Boffa","year":"2019","journal-title":"J Lipid Res"},{"issue":"05","key":"ref110","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/aje\/kwad232","article-title":"Inconsistency in UK biobank event definitions from different data sources and its impact on bias and generalizability: a case study of venous thromboembolism","volume":"193","author":"E Bassett","year":"2024","journal-title":"Am J Epidemiol"},{"issue":"06","key":"ref111","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1055\/a-2039-3222","article-title":"Developing validated tools to identify pulmonary embolism in electronic databases: rationale and design of the PE-EHR+ study","volume":"123","author":"B Bikdeli","year":"2023","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref112","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jtha.2024.10.013","article-title":"Validating International Classification of Diseases Code 10th Revision algorithms for accurate identification of pulmonary embolism","volume":"23","author":"B Bikdeli","year":"2025","journal-title":"J Thromb Haemost"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2019.08.015","article-title":"Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays","volume":"289","author":"H Scharnagl","year":"2019","journal-title":"Atherosclerosis"},{"issue":"02","key":"ref114","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1001\/archneur.1986.00520020056021","article-title":"Observations on the management of pseudotumor cerebri","volume":"43","author":"D A McGreal","year":"1986","journal-title":"Arch Neurol"},{"issue":"20","key":"ref115","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1161\/CIRCULATIONAHA.120.046397","article-title":"The effect of PCSK9 (proprotein convertase subtilisin\/kexin type 9) inhibition on the risk of venous thromboembolism","volume":"141","author":"N A Marston","year":"2020","journal-title":"Circulation"},{"issue":"06","key":"ref116","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1160\/TH15-10-0775","article-title":"Use of statins and reduced risk of recurrence of VTE in an older population. A population-based cohort study","volume":"115","author":"V Tagalakis","year":"2016","journal-title":"Thromb Haemost"},{"issue":"35","key":"ref117","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1093\/eurheartj\/ehae361","article-title":"Lipid lowering for prevention of venous thromboembolism: a network meta-analysis","volume":"45","author":"I T Farmakis","year":"2024","journal-title":"Eur Heart J"},{"issue":"02","key":"ref118","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1161\/01.ATV.0000151647.14923.ec","article-title":"Statins and blood coagulation","volume":"25","author":"A Undas","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"03","key":"ref119","first-page":"392","article-title":"Anticoagulant effects of statins and their clinical implications","volume":"111","author":"A Undas","year":"2014","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref120","first-page":"162","article-title":"Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. A systematic review and meta-analysis of randomised controlled trials","volume":"116","author":"A Sahebkar","year":"2016","journal-title":"Thromb Haemost"},{"issue":"11","key":"ref121","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.metabol.2016.08.007","article-title":"Effect of extended-release niacin on plasma lipoprotein(a) levels: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"65","author":"A Sahebkar","year":"2016","journal-title":"Metabolism"},{"issue":"08","key":"ref122","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","article-title":"Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial","volume":"28","author":"S J Nicholls","year":"2022","journal-title":"Nat Med"},{"issue":"09","key":"ref123","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1161\/ATVBAHA.117.309549","article-title":"CETP (cholesteryl ester transfer protein) inhibition with anacetrapib decreases production of lipoprotein(a) in mildly hypercholesterolemic subjects","volume":"37","author":"T Thomas","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"21","key":"ref124","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"A Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"issue":"03","key":"ref125","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"S Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"issue":"03","key":"ref126","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1001\/jama.2024.24017","article-title":"Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial","volume":"333","author":"S J Nicholls","year":"2025","journal-title":"JAMA"},{"issue":"20","key":"ref127","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"M L O'Donoghue","year":"2022","journal-title":"N Engl J Med"},{"issue":"23","key":"ref128","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/jama.2024.21957","article-title":"Zerlasiran\u2014a small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial","volume":"332","author":"S E Nissen","year":"2024","journal-title":"JAMA"},{"issue":"17","key":"ref129","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa2415818","article-title":"Lepodisiran\u2014a long-duration small interfering RNA targeting lipoprotein(a)","volume":"392","author":"S E Nissen","year":"2025","journal-title":"N Engl J Med"},{"issue":"20","key":"ref130","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/eurheartj\/ehx178","article-title":"Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial","volume":"38","author":"T Z Khan","year":"2017","journal-title":"Eur Heart J"},{"issue":"01","key":"ref131","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.thromres.2006.03.002","article-title":"Lipoprotein (a) in patients with spontaneous venous thromboembolism","volume":"120","author":"R Vormittag","year":"2007","journal-title":"Thromb Res"},{"issue":"25","key":"ref132","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.jacc.2016.10.033","article-title":"Phenotypic characterization of genetically lowered human lipoprotein(a) levels","volume":"68","author":"C A Emdin","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"08","key":"ref133","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jacc.2012.01.078","article-title":"Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism","volume":"60","author":"A Helgadottir","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"07","key":"ref134","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis","volume":"3","author":"S Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"ref135","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejim.2025.01.021","article-title":"Lipoprotein(a) and prothrombotic effects: evidence from a genetic association study","volume":"135","author":"E Olmastroni","year":"2025","journal-title":"Eur J Intern Med"},{"issue":"03","key":"ref136","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/cvr\/cvab078","article-title":"Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials","volume":"118","author":"P Joseph","year":"2022","journal-title":"Cardiovasc Res"},{"issue":"02","key":"ref137","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2352-3026(16)30184-3","article-title":"Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis","volume":"4","author":"S K Kunutsor","year":"2017","journal-title":"Lancet Haematol"},{"issue":"01","key":"ref138","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/jth.15537","article-title":"Statins for venous event reduction in patients with venous thromboembolism: A multicenter randomized controlled pilot trial assessing feasibility","volume":"20","author":"A Delluc","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"08","key":"ref139","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/ehjcvp\/pvae076","article-title":"Role of PCSK9 inhibitors in venous thromboembolism: current evidence and unmet clinical needs","volume":"10","author":"M Zuin","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"01","key":"ref140","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12916-017-0787-7","article-title":"Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials","volume":"15","author":"A Sahebkar","year":"2017","journal-title":"BMC Med"},{"issue":"04","key":"ref141","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.fjc.0000175875.48167.c7","article-title":"Effect of fenofibrate on lipoprotein(a) in hypertriglyceridemic patients: impact of change in triglyceride level and liver function","volume":"46","author":"H S Ko","year":"2005","journal-title":"J Cardiovasc Pharmacol"},{"issue":"9500","key":"ref142","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"A Keech","year":"2005","journal-title":"Lancet"},{"issue":"01","key":"ref143","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1038\/s41598-020-59903-6","article-title":"Author Correction: Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"A Sahebkar","year":"2020","journal-title":"Sci Rep"},{"issue":"04","key":"ref144","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40265-018-0870-1","article-title":"Effect of ezetimibe monotherapy on plasma lipoprotein(a) concentrations in patients with primary hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials","volume":"78","author":"K Awad","year":"2018","journal-title":"Drugs"},{"issue":"16","key":"ref145","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"F J Raal","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"ref146","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"K K Ray","year":"2020","journal-title":"N Engl J Med"},{"issue":"02","key":"ref147","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"K K Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"02","key":"ref148","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jacl.2023.02.002","article-title":"Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: a secondary analysis of the CLEAR harmony trial","volume":"17","author":"P M Ridker","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"04","key":"ref149","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/HCO.0000000000001137","article-title":"Effects of bempedoic acid on markers of inflammation and Lp(a)","volume":"39","author":"S Reddy","year":"2024","journal-title":"Curr Opin Cardiol"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2674-5114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:45:57Z","timestamp":1761867957000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2674-5114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":149,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,10,30]]},"published-print":{"date-parts":[[2025,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2674-5114","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]}}}